Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Showing results for "1"

News & Events

Sports star award

We are proud to have so many very talented children and youth in our T1D community.

News & Events

Meet Laurel

Leading international diabetes technology expert Laurel Messer visited Perth to share her experiences with closed loop systems at the Children’s Diabetes Centre’s Community Forum on March 28.

The Cashew Study

Does eating cashew nut spreads in the first year of life reduce the chances a baby will develop a cashew nut food allergy?

News & Events

PCH takes lead in Diabetes In Schools program

Perth Children’s Hospital will be one of the first hospitals in Australia to deliver critical diabetes training to teachers and school staff as part of a new national Diabetes in Schools program.

News & Events

ENDIA milestone

The ENDIA study — Australia’s largest study into the causes of Type 1 Diabetes— reached a significant milestone when it recruited its 700th patient in Perth.

Research

Resilience and Diabetes 2 (the RAD2 study)

Investigators: Anna Hunt, Ashleigh Lin  Stress and anxiety are significant problems in children and adolescence with type 1 diabetes. Not only do

News & Events

Perth's active T1D community

Despite the unseasonal weather, good turnouts were recorded for recent events organised by PMH and Diabetes WA.

Research

Control of mitophagy initiation and progression by the TBK1 adaptors NAP1 and SINTBAD

Mitophagy preserves overall mitochondrial fitness by selectively targeting damaged mitochondria for degradation. The regulatory mechanisms that prevent PTEN-induced putative kinase 1 (PINK1) and E3 ubiquitin ligase Parkin (PINK1/Parkin)-dependent mitophagy and other selective autophagy pathways from overreacting while ensuring swift progression once initiated are largely elusive. 

Research

Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE

The pivotal phase 3 EPITOPE trial, a 12-month, double-blind, placebo-controlled study of epicutaneous immunotherapy with the VIASKIN patch containing 250 μg of peanut protein (VP250), previously reported significant treatment response versus placebo in peanut-allergic toddlers aged 1 through 3 years.

News & Events

Teaching Kitchens

the Teaching Kitchens program will start again on Thursday March 9 from 5-7pm,  running for four weeks (every thursday evening).